Summary
Twenty-five patients with non-small cell lung cancer (NSCLC) were treated with high-dose methotrexate with citrovorum factor resuce (HDMTX-CFR), mechlorethamine (HN2) and procarbazine (PCZ). Nineteen patients are evaluable for response. One patient had partial remission which lasted for 11 weeks. Nine patients had stable disease lasting for 6–22 weeks. HDMTX-CFR was well tolerated by these patients but this combination regimen produced very low tumor response rate (5.2%). Addition of HN2 and PCZ, chemotherapeutic agents active against NSCLC, failed to improve the tumor response rate but added to gastrointestinal and hematologic toxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bitran JD, Desser RK, DeMesster T, Golomb HM (1978) Metastatic non-oat cell bronchogenic carcinoma. Therapy with cyclophosphamide, doxorubicin, methotrexate and procarbazine (CAMP). JAMA 240:2743
Djerrassi I, Rominger CJ, Kim JS, Turchi J, Suvansri V, Highes D (1972) Phase I study of high doses of methotrexate with citrovorum factor in patients with lung cancer. Cancer 30:22
Djerassi I, Kim JS, Ohanissian H (1978) High-dose methotrexate (HDMTX) and citrovorum factor rescue (CFR) in solid tumors. Chemisterapia Oncologia [suppl 2] 4:243
Ettinger DS, Stanley DE, Nystrom JS (1980) Phase II study of patients with non-small cell carcinoma of the lung: An eastern cooperative oncology group study. Cancer Treat Rep 64:1017
Greco FA, Fer MF, Richardson RL, Hande KR, Van Boxtel CJ, Oldham RK (1978) High-dose methotrexate with citrovorum factor rescue in non-small cell lung cancer. Cancer Chemother Pharmacol 1:255
Isacoff WH, Eilber F, Tabbarah H, Klein P, Dollinger M, Lemkin S, Sheehy P, Cone L, Rosenbloom B, Sieger L, Block JB (1978) Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue. Cancer Treat Rep 62:1295
Minna J, Pelsor F, Ihde D, Bunn P, Gazdar A, Cohen M (1978) High-dose methotrexate (HDMTX) therapy by 6- or 30-hour infusion with leucovorin rescue (LR) in non-small cell lung cancer. Proc AACR/ASCO 19:135
Volgelzang JH, Bonomi PD, Rossof AH, Wolter J (1978) Cyclophosphamide, adriamycin, methotrexate and procarbazine (CAMP) treatment of non-oat cell bronchogenic carcinoma. Cancer Treat Rep 62:1595
Samuels ML, Leary WV, Howe CD (1969) Procarbazine (NSC-77213) in the treatment of advanced bronchogenic carcinoma. Cancer Chemother Rep 53:135–145
Selawry OS (1973) Monochemotherapy of bronchogenic carcinoma with special reference to cell type. Cancer Chemother Rep 4:177–188
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bhasin, R.R., Nogeirie, C.P. Combination chemotherapy (high-dose methotrexate with citrovorum factor rescue, mechlorethamine, and procarbazine) in non-small cell lung cancer. Cancer Chemother. Pharmacol. 11, 106–107 (1983). https://doi.org/10.1007/BF00254256
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00254256